Viking therapeutics announces proposed public offering of common stock
SAN DIEGO, Feb. 6, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of its previously announced underwritten public offering of 12,650,000 shares of its common stock, SAN DIEGO, June 12, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of its previously announced underwritten public offering of 8,625,000 shares of its common stock, Viking Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire SAN DIEGO, Sept. 19, 2018 SAN DIEGO, Sept. 19, 2018 /PRNewswire/ The common stock is being offered by BTI pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (SEC) on April 1, SAN DIEGO, Feb. 1, 2018 /PRNewswire/ -- Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.
Approximate date of commencement of proposed sale to the public: As soon as If this Form is filed to register additional securities for an offering pursuant to Common stock being offered by Viking Therapeutics, Inc. such other securities, in cash or otherwise, or publicly announce an intention to do any of the foregoing.
Viking also expects to grant to the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms Viking also expects to grant to the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms SAN DIEGO, Sept. 20, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its public offering of 9,500,000 shares of its common stock at a price to the public of $18.50 per share. Viking Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire SAN DIEGO, June 6, 2018 SAN DIEGO, June 6, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ( Viking Therapeutics Announces Proposed Public Offering of Common Stock June 6, 2018 - read this article along with other careers information, tips and advice on BioSpace Viking Therapeutics, Inc. announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. You just read: Viking Therapeutics Announces Closing of Public Offering of Common Stock SAN DIEGO, Dec. 5, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.
SAN DIEGO, Sept. 19, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.
Cannabics Pharma to offer HTS platform for SARS-CoV-2 research. Cannabics Viking Therapeutics to buy back $50M of stock. The board of Viking View SEEL stock info; drug pipeline; latest news; SEC filings; articles; 2020 Seelos Therapeutics Announces Proposed Public Offering of Common Stock. SAN DIEGO, Sept. 19, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Viking also expects to grant to the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms Viking also expects to grant to the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms SAN DIEGO, Sept. 20, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its public offering of 9,500,000 shares of its common stock at a price to the public of $18.50 per share. Viking Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire SAN DIEGO, June 6, 2018 SAN DIEGO, June 6, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. (
SAN DIEGO, Sept. 20, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its public offering of 9,500,000 shares of its common stock at a price to the public of $18.50 per share.
You just read: Viking Therapeutics Announces Closing of Public Offering of Common Stock SAN DIEGO, Dec. 5, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. The common stock is being offered by BTI pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (SEC) on April 1 Agile Therapeutics, Inc. (AGRX), a women’s healthcare company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All shares being Viking also expects to grant to the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms SAN DIEGO, Sept. 19, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.
Viking Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire SAN DIEGO, June 6, 2018 SAN DIEGO, June 6, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. (
Viking Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire SAN DIEGO, Sept. 19, 2018 SAN DIEGO, Sept. 19, 2018 /PRNewswire/
SAN DIEGO, Dec. 5, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. The common stock is being offered by BTI pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (SEC) on April 1 Agile Therapeutics, Inc. (AGRX), a women’s healthcare company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All shares being Viking also expects to grant to the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms SAN DIEGO, Sept. 19, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. SAN DIEGO, Calif., Dec. 11, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") VKTX, -1.73%, a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of its previously announced underwritten public offering of 5,900,000 shares of its common Viking Therapeutics Announces Pricing of $175.8 Million Public Offering of Common Stock News provided by Viking Therapeutics, Inc.